Academic Health Center
Stay Connected
research-and-clinical-trials

Research Snapshot: Depression screening in older adults

The number of antidepressants prescribed in the U.S. is skyrocketing as more primary care providers give antidepressants to patients even though many of them don’t have a psychiatric diagnosis.

A group of University of Minnesota researchers set out to study how that trend might be affecting older adults.

Read more
expert-perspectives

Few teens receive medication-assisted treatment for opioid addiction

Less than one percent of adolescents addicted to opiates receive medications to help them quit, new research shows.  The Journal of Adolescent Health says that’s compared to 12 percent of adults that receive medication.

Read more
expert-perspectives

‘Overdose antidote’ naloxone marks one year of availability in Minnesota

It has now been one full year since naloxone, commonly known as Narcan, has been available at pharmacies here in Minnesota. The increased availability of the life-saving drug has made a difference according to medical professionals at the University of Minnesota.

Read more
research-and-clinical-trials

Review: Alpha blockers helpful in treating kidney stones

A new review published this week in The BMJ suggests that alpha blockers are also a beneficial treatment for patients who find themselves in the emergency room with a kidney stone that has dropped into their ureter, a thin tube that transports urine from the kidney to bladder. This medication appears to work particularly if the kidney stone is large.

Read more
in-the-news

In the News: University of Minnesota research drives home aspirin’s benefits

Despite its known benefits, new research from the University of Minnesota’s Medical School shows many older patients don’t talk to their doctors about the cardiovascular benefits of low-dose aspirin.

The study, published in the Journal of the American Heart Association, looked at aspirin use of 26,000 Minnesotans ages 25 to 74. The study found aspirin use for primary prevention of heart attacks and stroke increased in men from 1 percent in 1980 to 21 percent in 2009, and in women from 1 percent to 12 percent.

Read more
in-the-news

In the News: Drug manufacturers fail to report serious side effects within 15-day time period

Drug manufacturers are required to disclose serious side effects and unexpected adverse events to the U.S. Food and Drug Administration (FDA) within 15 days of being notified by a patient. However, a recent study at the University of Minnesota’s School of Public Health in collaboration with Stanford Graduate School of Business and the Carlson School of Management, found 1 in 10 companies fail to comply with these regulations.

The research, referenced in a recent Star Tribune article, analyzed 1.6 million reports from drug manufacturers between 2004 and 2014. Results showed the companies were less likely to disclose the reports to the FDA if the side effects were fatal.

Read more